Role of Tyrosine Kinase Inhibitors in Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 5, 2009-06 ,pp. : 569-575

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

By Kirkali Ziya   Tüüzel Emre  

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 871-888

Future Medicine

Access to resources Recommend Favorite

Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 1, 2009-01 ,pp. : 66-76

Bentham Science Publishers

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite